NASDAQ:CDLXCardlytics Stock Price, Forecast & News

Cardlytics' stock was trading at $45.83 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, CDLX shares have increased by 53.5% and is now trading at $70.33. View which stocks have been most impacted by Coronavirus.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cardlytics in the last year. There are currently 1 sell rating, 3 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Cardlytics.

Cardlytics is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Cardlytics.

Cardlytics Inc (NASDAQ:CDLX) released its earnings results on Monday, May, 11th. The company reported ($0.26) EPS for the quarter, beating the consensus estimate of ($0.35) by $0.09. The company had revenue of $45.51 million for the quarter, compared to analyst estimates of $42.97 million. Cardlytics had a negative net margin of 11.08% and a negative return on equity of 19.42%. The business's quarterly revenue was up 26.5% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.23) EPS. View Cardlytics' earnings history.

6 equities research analysts have issued 1 year price objectives for Cardlytics' stock. Their forecasts range from $26.00 to $55.00. On average, they expect Cardlytics' share price to reach $48.50 in the next year. This suggests that the stock has a possible downside of 31.0%. View analysts' price targets for Cardlytics.

Media stories about CDLX stock have been trending negative this week, according to InfoTrie. The research firm identifies positive and negative media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Cardlytics earned a media sentiment score of -2.1 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View the latest news about Cardlytics.

Some companies that are related to Cardlytics include Legend Biotech (DADA), HUYA (HUYA), Switch (SWCH), DouYu International (DOYU), Medallia (MDLA), SVMK (SVMK), 21Vianet Group (VNET), Pluralsight (PS), Tripadvisor (TRIP), Sabre (SABR), Internet Initiative Japan (IIJIY), Model N (MODN), Qutoutiao (QTT), Health Catalyst (HCAT) and The Rubicon Project (RUBI). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Cardlytics investors own include Alibaba Group (BABA), Trade Desk (TTD), Advanced Micro Devices (AMD), NVIDIA (NVDA), Caterpillar (CAT), Roku (ROKU), Micron Technology (MU), Netflix (NFLX), Square (SQ) and Walt Disney (DIS).

(CDLX) raised $76 million in an IPO on Friday, February 9th 2018. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. BofA Merrill Lynch and J.P. Morgan acted as the underwriters for the IPO and Wells Fargo Securities, SunTrust Robinson Humphrey, Raymond James and KeyBanc Capital Markets were co-managers.

Cardlytics trades on the NASDAQ under the ticker symbol "CDLX."

Shares of CDLX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of CDLX stock can currently be purchased for approximately $70.33.

Cardlytics has a market capitalization of $1.90 billion and generates $210.43 million in revenue each year. The company earns $-17,140,000.00 in net income (profit) each year or ($0.75) on an earnings per share basis.

The official website for Cardlytics is www.cardlytics.com.

Cardlytics' mailing address is 675 PONCE DE LEON AVENUE NE SUITE 6000, ATLANTA GA, 30308. The company can be reached via phone at 888-798-5802 or via email at [email protected]